The disruption of the CCDC6 – PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma

The disruption of the CCDC6 – PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma

Abstract Background Treatment with PARP inhibitors (PARPi) is primarily effective against high-grade serous ovarian cancers (HGSOC) with BRCA1/2 mutations or other deficiencies in homologous recombination (HR) repair mechanisms. However, resistance to PARPi frequently develops, mostly as a result of...

Full description

Bibliographic Details
Main Authors: Francesco Morra, Francesco Merolla, Giovanna Damia, Francesca Ricci, Silvia Varricchio, Gennaro Ilardi, Laura Arenare, Daniela Califano, Virginia Napolitano, Robert Fruscio, Rosa Marina Melillo, Luca Palazzo, Angela Celetti
Format: Article
Language:English
Published: BMC 2022-08-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Biomarker
PARP inhibitors
Cisplatin
Drugs resistance
PDX
PP4
Online Access:https://doi.org/10.1186/s13046-022-02459-2

Similar Items

Similar Items